Impact of Pharmacist Instruction on Phosphate Levels

A single-arm pre-post study involving chronic dialysis patients (≥18 years) using phosphate binders was conducted at a Norwegian hospital. The primary endpoint was the change in the proportion of patients achieving serum phosphate levels below 1.80 mmol/L. Changes in patient beliefs, knowledge, and adherence as determined by questionnaires (Patient Knowledge. Medication Adherence Report Scale – MARS-5, Beliefs about Medicines Questionnaire – BMQ) were among the secondary objectives. Before and after pharmacist-led instruction, data were gathered, and additional drugs taken were registered.

There were 69 patients in the trial. Although not statistically significant, there was a higher likelihood of obtaining serum phosphate levels < 1.80 mmol/L following the intervention. Patients’ views on the need for therapy and their knowledge of phosphate binder treatment both rose, but their fears declined (BMQ). Nevertheless, as self-reported adherence was already high prior to the intervention, this did not result in a statistically significant increase as measured by MARS-5.
lass=”yoast-text-mark” The likelihood of reaching goal serum phosphate levels was increased by brief, one-on-one instruction from pharmacists, however this effect was not statistically significant. The average serum phosphate levels did not drop, and the degree of self-reported adherence did not decline. However, patients demonstrated increased knowledge about phosphate binders, improved understanding of adherence, and reduced concerns about medication side effects (Hjemås et al., 2019).

Kendrick and colleagues conducted a study titled “A one-year historical cohort study of the phosphate. Binder sucroferric oxyhydroxide in patients on maintenance hemodialysis” aimed to evaluate the real-world. Effectiveness of sucroferric oxyhydroxide (SO), a phosphate binder with a low pill burden, in managing serum phosphorus in prevalent hemodialysis patients over one 1-year. This involved historical cohort analyses based on de-identified electronic medical records.
In-center hemodialysis patients who transitioned from another phosphate binder to. SO therapy as part of routine care, with 12 months of uninterrupted SO prescriptions recorded and documented serum phosphorus levels, were eligible for inclusion. The 91-day window prior to SO beginning (baseline) and four successive 91-day windows of SO therapy (Q1–Q4) wereAPA